Aurobindo Pharma has received the final approval from USFDA for Raloxifene Hydrochloride tablets, which is bio-equivalent and therapeutic equivalent to the reference listed drug product (RLD) Evista tablets of Eli Lilly.
The drug is indicated for treatment and prevention of osteoporosis in post-menopausal women.
The product has an estimated market size of $404 million. The company now has a total of 210 ANDA approvals (182 final approvals including nine from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply